Lancet Respiratory Medicine最新文献

筛选
英文 中文
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study Retifanlimab与安慰剂联合铂基化疗治疗一线非鳞状或鳞状转移性非小细胞肺癌(POD1UM-304):一项多区域、安慰剂对照、双盲、随机的3期研究
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-09-19 DOI: 10.1016/s2213-2600(25)00209-7
Shun Lu, Oleksandr Vynnychenko, Yaroslav Kulyaba, Vladimer Kuchava, Aishah Ibrahim, Fedor Moiseenko, Cagatay Arslan, Duong Thanh Nguyen, Marina Petrovic, Irfan Cicin, Khatuna Bibichadze, Timucin Cil, Jianhua Shi, Omer Fatih Olmez, Miranda Gogishvili, Mehmet Artac, Hoang Gia Nguyen, Mark Cornfeld, Chuan Tian, Mihaela C Munteanu, Igor Bondarenko
{"title":"Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study","authors":"Shun Lu, Oleksandr Vynnychenko, Yaroslav Kulyaba, Vladimer Kuchava, Aishah Ibrahim, Fedor Moiseenko, Cagatay Arslan, Duong Thanh Nguyen, Marina Petrovic, Irfan Cicin, Khatuna Bibichadze, Timucin Cil, Jianhua Shi, Omer Fatih Olmez, Miranda Gogishvili, Mehmet Artac, Hoang Gia Nguyen, Mark Cornfeld, Chuan Tian, Mihaela C Munteanu, Igor Bondarenko","doi":"10.1016/s2213-2600(25)00209-7","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00209-7","url":null,"abstract":"<h3>Background</h3>Checkpoint inhibitors, including combinations with standard-of-care chemotherapy, have shown survival benefit in patients with metastatic non-small-cell lung cancer (NSCLC); however, access to these drugs varies. We aimed to evaluate the efficacy of the PD-1 inhibitor retifanlimab plus platinum-based chemotherapy as first-line treatment for non-squamous or squamous metastatic NSCLC.<h3>Methods</h3>POD1UM-304 was a phase 3, multiregional, placebo-controlled, double-blind, randomised study conducted in approximately 124 hospitals and private clinical centres in 16 countries. Male and female adults aged 18 years or older with squamous or non-squamous stage IV NSCLC (staging by American Joint Committee on Cancer version 8) with Eastern Cooperative Oncology Group performance status 0 or 1 and no previous systemic therapy for metastatic NSCLC were eligible. Patients were randomly assigned (2:1) using interactive response technology to receive intravenous retifanlimab 375 mg or matching placebo on day 1 of each 21-day cycle plus standard platinum-based chemotherapy according to tumour histology for up to 2 years. Patients with non-squamous NSCLC received pemetrexed 500 mg/m<sup>2</sup> plus cisplatin 75 mg/m<sup>2</sup> on day 1 for four cycles, or carboplatin area under the curve (AUC) 5 on day 1 for four cycles, followed by pemetrexed 500 mg/m<sup>2</sup> on day 1 of each subsequent 21-day cycle, all administered intravenously, until disease progression or unacceptable toxicity. Patients with squamous NSCLC received intravenous carboplatin AUC 6 plus intravenous paclitaxel 200 mg/m<sup>2</sup> on day 1 for four cycles or intravenous nab-paclitaxel 100 mg/m<sup>2</sup> on days 1, 8, and 15 for four cycles. Treatment with retifanlimab or placebo was given for up to 35 cycles, unless there was disease progression, unacceptable toxicity, or withdrawal of consent. Randomisation was stratified by PD-L1 expression tumour proportion score, geographical region, and predominant tumour histology. The primary endpoint was overall survival, defined as time from randomisation until death due to any cause, analysed in the full analysis set. Safety was evaluated in all randomly assigned patients who received at least one dose of study drug. This trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT04205812</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>) and is active but no longer enrolling.<h3>Findings</h3>Between Sept 11, 2020, and March 14, 2023, 1388 patients were assessed for eligibility, 583 of whom were randomly assigned to retifanlimab plus chemotherap","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"154 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145089025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
US states and medical societies chart new paths forward amid turmoil at CDC and ACIP 在疾控中心和ACIP的动荡中,美国各州和医学协会制定了新的前进道路
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-09-10 DOI: 10.1016/s2213-2600(25)00332-7
Bryant Furlow
{"title":"US states and medical societies chart new paths forward amid turmoil at CDC and ACIP","authors":"Bryant Furlow","doi":"10.1016/s2213-2600(25)00332-7","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00332-7","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"51 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chrysotile asbestos—the deadly consequences of a retreat from national bans 温石棉——撤销国家禁令的致命后果
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-09-04 DOI: 10.1016/s2213-2600(25)00301-7
Anthony Linton, Shane McArdle, Kim Brislane, Deborah Yates
{"title":"Chrysotile asbestos—the deadly consequences of a retreat from national bans","authors":"Anthony Linton, Shane McArdle, Kim Brislane, Deborah Yates","doi":"10.1016/s2213-2600(25)00301-7","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00301-7","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"42 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between CFTR variants, sweat chloride responses, and lung function improvements CFTR变异、汗液氯化物反应和肺功能改善的关系
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-09-03 DOI: 10.1016/s2213-2600(25)00208-5
Anna-Maria Dittrich
{"title":"Relationship between CFTR variants, sweat chloride responses, and lung function improvements","authors":"Anna-Maria Dittrich","doi":"10.1016/s2213-2600(25)00208-5","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00208-5","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"29 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144987553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sweat chloride and lung function responses to elexacaftor–tezacaftor–ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies 囊性纤维化患者两种与一种应答性CFTR变异体的汗氯化物和肺功能反应:两项现实世界观察性研究的分析
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-09-03 DOI: 10.1016/s2213-2600(25)00190-0
Pierre-Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, Isabelle Durieu, Martine Reynaud-Gaubert, Marlene Murris-Espin, Raphael Chiron, Dominique Grenet, Sophie Ramel, Laurent Mely, Rebecca Hamidfar, Benoit Douvry, Véronique Houdouin, Camille Audousset, Julie Macey, Marie Mittaine, Laurence Weiss, Laure Cosson, Isabelle Danner-Boucher, Philippe Reix, Anne-Sophie BONNEL
{"title":"Sweat chloride and lung function responses to elexacaftor–tezacaftor–ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies","authors":"Pierre-Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, Isabelle Durieu, Martine Reynaud-Gaubert, Marlene Murris-Espin, Raphael Chiron, Dominique Grenet, Sophie Ramel, Laurent Mely, Rebecca Hamidfar, Benoit Douvry, Véronique Houdouin, Camille Audousset, Julie Macey, Marie Mittaine, Laurence Weiss, Laure Cosson, Isabelle Danner-Boucher, Philippe Reix, Anne-Sophie BONNEL","doi":"10.1016/s2213-2600(25)00190-0","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00190-0","url":null,"abstract":"<h3>Background</h3>Among people with cystic fibrosis, sweat chloride and lung function response to elexacaftor–tezacaftor–ivacaftor (ETI) is variable. We hypothesised that the presence of two versus one ETI-responsive <em>CFTR</em> variant could predict response variability.<h3>Methods</h3>In this analysis of two real-world observational studies, data from a French national cohort of adults (aged ≥18 years) with cystic fibrosis and at least one F508del variant treated with ETI and the French compassionate programme for ETI in people (aged ≥6 years) with cystic fibrosis without F508del were used to examine sweat chloride concentrations (SCCs) after ETI initiation, and the absolute change in SCC and percentage of predicted forced expiratory volume in 1 s (ppFEV<sub>1</sub>) following ETI initiation. The ETI responsiveness of <em>CFTR</em> variants was determined following the French compassionate programme's classification.<h3>Findings</h3>Among 1266 participants, 834 had two ETI-responsive variants and 432 had only one. Median SCC after ETI initiation was 36 mmol/L (IQR 24–50) in participants with two ETI-responsive variants and 53 mmol/L (26–72) in those with only one (p&lt;0·0001). The proportion of participants with SCC of less than 30 mmol/L was 298 (36%) of 834 among those with two ETI-responsive variants and 65 (15%) of 432 in those with one ETI-responsive variant (χ<sup>2</sup> p&lt;0·00001). Multivariable analyses showed that the number of ETI-responsive variants was a determinant of SCC after ETI initiation (p&lt;0·0001) but not of the absolute change in ppFEV<sub>1</sub> (p=0·80).<h3>Interpretation</h3>People with cystic fibrosis with two responsive <em>CFTR</em> variants had a better correction of CFTR function in sweat glands after ETI initiation than those with only one responsive variant, but the response in terms of ppFEV<sub>1</sub> was similar. These findings suggest that maximal improvement in lung function could be reached with current CFTR modulators and that no further increase in lung function would be expected from more potent restoration of CFTR function. Reaching normal lung function in people with cystic fibrosis and established lung disease might be limited by irreversible lung damage, suggesting that new therapeutic strategies aimed at improving lung function should be developed.<h3>Funding</h3>Association Vaincre la Mucoviscidose, Société Française de la Mucoviscidose, and Filière Maladies Rares MUCO-CFTR.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"48 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144987552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study 支气管扩张的症状、未来恶化的风险和对长期大环内酯治疗的反应:一项观察性研究
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-08-27 DOI: 10.1016/s2213-2600(25)00160-2
Oriol Sibila, Jamie Stobo, Lidia Perea, Yong-Hua Gao, Jin-Fu Xu, Holly Lind, Kateryna Viligorska, Arietta Spinou, Eva Polverino, Felix C Ringshausen, Montserrat Vendrell, Pierre-Régis Burgel, Charles S Haworth, Michael R Loebinger, Natalie Lorent, Raja Dhar, Hayoung Choi, Sanjay H Chotirmall, Anthony De Soyza, John R Hurst, James D Chalmers
{"title":"Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study","authors":"Oriol Sibila, Jamie Stobo, Lidia Perea, Yong-Hua Gao, Jin-Fu Xu, Holly Lind, Kateryna Viligorska, Arietta Spinou, Eva Polverino, Felix C Ringshausen, Montserrat Vendrell, Pierre-Régis Burgel, Charles S Haworth, Michael R Loebinger, Natalie Lorent, Raja Dhar, Hayoung Choi, Sanjay H Chotirmall, Anthony De Soyza, John R Hurst, James D Chalmers","doi":"10.1016/s2213-2600(25)00160-2","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00160-2","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Previous studies have suggested that daily symptoms are a marker of bronchiectasis disease activity and could therefore identify patients at increased risk of exacerbation. However, international bronchiectasis guidelines recommend long-term macrolide treatment only in patients with three or more exacerbations per year. We aimed to investigate if symptoms independently predict future exacerbations and therefore identify additional responders to long-term macrolide treatment.&lt;h3&gt;Methods&lt;/h3&gt;We used data from the EMBARC registry, a multicentre international bronchiectasis database. Baseline symptoms were evaluated with the quality-of-life bronchiectasis questionnaire respiratory symptoms score (QoL-B-RSS), followed-up for at least 1 year, and were related to the future risk of exacerbations. We subsequently conducted a post-hoc pooled analysis of three randomised controlled trials of macrolides (ie, BLESS, BAT, and EMBRACE) in 341 participants with bronchiectasis to determine if baseline symptoms were associated with response to long-term macrolide treatment, using a negative binomial regression model.&lt;h3&gt;Findings&lt;/h3&gt;9466 patients from the 19 324 patients included in the EMBARC registry had available QoL-B-RSS assessment at baseline and 1-year follow-up. The median age was 68 years (IQR 58–74), 5763 (60·9%) were female, and 3703 (39·1%) were male. The median Bronchiectasis Severity Index score was 7 (4–10) and &lt;em&gt;Pseudomonas aeruginosa&lt;/em&gt; was present in the sputum of 2041 (21·6%) patients within 12-months of baseline. Previous exacerbations (rate ratio (RR) for every additional exacerbation 1·11, 95% CI 1·10–1·12; p&lt;0·0001) and symptoms (RR for every 10 points lower QoL-B-RSS 1·10, 1·09–1·11; p&lt;0·0001) were identified as independent risk factors for future exacerbations. The number of exacerbations during 1-year of follow-up was similar between patients with three or more exacerbations at baseline and average symptom scores (QoL-B-RSS 60–70; RR 1·58, 95% CI 1·48–1·69) and the group with no previous exacerbations but high symptom scores (RR 1·55, 1·41–1·70). The same pattern was observed in the post-hoc analysis of randomised controlled trials, both in the macrolide and placebo groups. The number-needed-to-treat to prevent exacerbations with long-term macrolide therapy was similar for patients selected based on frequent exacerbations (1·45, 95% CI 1·08–2·24) and in those with few previous exacerbations, but high symptom scores 1·43 (1·06–2·18).&lt;h3&gt;Interpretation&lt;/h3&gt;Our results suggest that symptoms are an independent risk factor for future exacerbations in bronchiectasis. Patients who are highly symptomatic derive a similar benefit from macrolide treatment as patients with a high baseline exacerbation frequency.&lt;h3&gt;Funding&lt;/h3&gt;EU, European Federation of Pharmaceutical Industries and the Associations Innovative Medicines Initiative Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis Consortium, European Respiratory","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"15 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144910998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A deep dive into existing data to inform clinical practice for adults with bronchiectasis 深入研究现有数据,为成人支气管扩张的临床实践提供信息
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-08-27 DOI: 10.1016/s2213-2600(25)00244-9
Anne B Chang
{"title":"A deep dive into existing data to inform clinical practice for adults with bronchiectasis","authors":"Anne B Chang","doi":"10.1016/s2213-2600(25)00244-9","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00244-9","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"160 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144910999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Projecting the 30-year burden of obstructive sleep apnoea in the USA: a prospective modelling study 预测美国30年的阻塞性睡眠呼吸暂停负担:一项前瞻性模型研究
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-08-26 DOI: 10.1016/s2213-2600(25)00243-7
Elroy Boers, Meredith A Barrett, Adam V Benjafield, Jodi H Barnet, Laurel A Ravelo, Leanne Kaye, Peter A Cistulli, Jean-Louis Pépin, Jeff Armitstead, Kimberly L Sterling, Carlos M Nunez, Paul E Peppard, Atul Malhotra
{"title":"Projecting the 30-year burden of obstructive sleep apnoea in the USA: a prospective modelling study","authors":"Elroy Boers, Meredith A Barrett, Adam V Benjafield, Jodi H Barnet, Laurel A Ravelo, Leanne Kaye, Peter A Cistulli, Jean-Louis Pépin, Jeff Armitstead, Kimberly L Sterling, Carlos M Nunez, Paul E Peppard, Atul Malhotra","doi":"10.1016/s2213-2600(25)00243-7","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00243-7","url":null,"abstract":"<h3>Background</h3>Obstructive sleep apnoea is a common disorder that is associated with major public health and economic burden across the USA. Previous studies have assessed the prevalence of the condition. In the present study, we aimed to estimate the burden of obstructive sleep apnoea across the USA from 2020 to 2050, to guide public health policies and management pathways.<h3>Methods</h3>In this prospective modelling study, historical data on obstructive sleep apnoea prevalence in the USA were extracted from a previously published longitudinal cohort study. US population characteristics (age and sex) were obtained from relevant and validated population data sources, and data on BMI were obtained from the National Health and Nutrition Examination Survey and the Wisconsin Sleep Cohort. To project the obstructive sleep apnoea burden (cases and prevalence) into 2050, we developed an open cohort dynamic population simulation model.<h3>Findings</h3>On the basis of projected changes in US age, sex, and BMI population distributions, the model predicts a significant rise in obstructive sleep apnoea over the next three decades. By 2050, the prevalence of obstructive sleep apnoea (apnoea–hypopnoea index ≥5/h) is expected to show a relative increase of 34·7%, from 34·3% (95% uncertainty interval [UI] 34·0–34·4) to 46·2% (46·0–46·4), resulting in 76·6 million cases. We estimate that females will see a larger relative increase than males, with a 65·4% relative increase in prevalence, from 22·8% (22·5–23·0) to 37·7% (37·4–38·0) reaching a total of 30·4 million cases. Males are projected to show a more moderate relative increase of 19·3%, from 45·6% (45·4–46·0) to 54·4% (54·2–54·7), reaching 45·9 million cases.<h3>Interpretation</h3>Projections indicate that obstructive sleep apnoea will affect 76·6 million adults aged 30–69 years across the USA in 2050, with a disproportionate growth among females compared with males. These findings highlight the urgent need for targeted public health strategies and revised access to diagnosis and follow-up pathways to address the growing prevalence of obstructive sleep apnoea, particularly among females.<h3>Funding</h3>Resmed.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"27 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Driving forwards in the management of OSA 推动OSA的管理
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-08-26 DOI: 10.1016/s2213-2600(25)00302-9
{"title":"Driving forwards in the management of OSA","authors":"","doi":"10.1016/s2213-2600(25)00302-9","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00302-9","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"18 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forecasting the burden of obstructive sleep apnoea 预测阻塞性睡眠呼吸暂停的负担
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-08-26 DOI: 10.1016/s2213-2600(25)00265-6
Ye Zhang, Virend K Somers, Xiangdong Tang
{"title":"Forecasting the burden of obstructive sleep apnoea","authors":"Ye Zhang, Virend K Somers, Xiangdong Tang","doi":"10.1016/s2213-2600(25)00265-6","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00265-6","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"18 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信